Get the Stockscreener App
4.51
9.47%
0.39
Foghorn Therapeutics Inc stock is traded at $4.51, with a volume of 124.86K.
It is up +9.47% in the last 24 hours and down -3.84% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$4.12
Open:
$4.11
24h Volume:
124.86K
Relative Volume:
0.86
Market Cap:
$229.12M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-1.9274
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
+7.64%
1M Performance:
-3.84%
6M Performance:
-10.52%
1Y Performance:
+44.55%
1-Day Range:
$4.09
$4.53
1-Week Range:
$3.89
$4.56
52-Week Range:
$3.50
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.50 | 229.12M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.09 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.63 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.98 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.32 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.92 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Upgraded by B. Riley - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Coverage Initiated by Analysts at B. Riley - MarketBeat
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains? - Yahoo Finance
Foghorn Therapeutics Advances Drug Development in Oncology - TipRanks
What is B. Riley’s Estimate for FHTX FY2024 Earnings? - Defense World
What is B. Riley's Estimate for FHTX FY2024 Earnings? - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at B. Riley - Defense World
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Target Price at $13.17 - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Upgraded at B. Riley - Defense World
Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Foghorn Therapeutics a new buy at B Riley on tumor fighting technology - Seeking Alpha
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
B. Riley Initiates Foghorn Therapeutics at Buy With $10 Price Target -January 30, 2025 at 07:56 am EST - Marketscreener.com
Foghorn Therapeutics receives Nasdaq compliance notice - MSN
Foghorn Therapeutics receives Nasdaq compliance notice By Investing.com - Investing.com Australia
Foghorn Therapeutics (FHTX) Stock Price, News & Analysis - MarketBeat
Barclays PLC Grows Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Sold by Jane Street Group LLC - Defense World
Foghorn Therapeutics Sets 2025 Strategic Objectives - TipRanks
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025 - The Manila Times
Barclays PLC Acquires 26,228 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Geode Capital Management LLC - Defense World
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Expands By 6.8% - MarketBeat
More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41% - Simply Wall St
Foghorn Therapeutics announces director resignation - Investing.com India
Foghorn Therapeutics announces director resignation By Investing.com - Investing.com Nigeria
Foghorn Therapeutics Board Member Resignation Announced - TipRanks
State Street Corp Grows Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
XTX Topco Ltd Buys Shares of 10,900 Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FY2028 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World
HC Wainwright Has Positive Forecast for FHTX FY2024 Earnings - Defense World
Charles Schwab Investment Management Inc. Grows Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Wedbush Reduces Earnings Estimates for Foghorn Therapeutics - MarketBeat
HC Wainwright Issues Optimistic Estimate for FHTX Earnings - MarketBeat
Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright - Yahoo Finance
Short Interest in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Decreases By 9.7% - MarketBeat
Foghorn Therapeutics shares target cut, buy rating on positive outlook By Investing.com - Investing.com Canada
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Foghorn Therapeutics Inc Stock (FHTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Costa Carlos | Chief People Officer |
Sep 23 '24 |
Option Exercise |
3.72 |
857 |
3,188 |
857 |
| Costa Carlos | Chief People Officer |
Sep 20 '24 |
Sale |
10.04 |
35,756 |
358,990 |
0 |
| Costa Carlos | Chief People Officer |
Sep 23 '24 |
Sale |
10.17 |
857 |
8,716 |
0 |
| Costa Carlos | Chief People Officer |
Sep 18 '24 |
Option Exercise |
3.72 |
11,574 |
43,055 |
11,574 |
| Costa Carlos | Chief People Officer |
Sep 18 '24 |
Sale |
10.05 |
11,574 |
116,319 |
0 |
| Costa Carlos | Chief People Officer |
Sep 17 '24 |
Option Exercise |
3.72 |
10,272 |
38,212 |
10,272 |
| Costa Carlos | Chief People Officer |
Sep 16 '24 |
Option Exercise |
3.72 |
400 |
1,488 |
400 |
| Costa Carlos | Chief People Officer |
Sep 17 '24 |
Sale |
10.04 |
10,272 |
103,131 |
0 |
| Costa Carlos | Chief People Officer |
Sep 16 '24 |
Sale |
10.00 |
400 |
4,000 |
0 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):